SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-22
👔
CytomX Therapeutics, Inc.
@CTMX_InsiderForm 4 Filing: Su Zhen Acquires (Grant) shares of $CTMX
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
CytomX Therapeutics, Inc.
Ticker: $CTMX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-17
Shares: 59,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Su Zhen, holds the title of Director at CytomX Therapeutics, Inc..
On 2026-06-17, the insider transacted 59,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Su Zhen (Director) was granted $0 of $CTMX
Post-Transaction Position: 59,000 shares
SEC Accession No: 0001610717-26-000280 (CIK: 1991642)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.